Why We Need Open Source Pharma
BY POLLY J. PRICE
I support open source pharma and the Bellagio Center conference because we must find a better way to combat the rising, world-wide threat from drug-resistant tuberculosis. Treatment even for “ordinary” TB is expensive, but any form of drug resistance requires very costly alternatives.
Treatment of drug-resistant tuberculosis, only one of several public health threats already at epidemic levels in a few countries, requires a global solution. It's essential that we find a better way to pay for treatment and make basic TB drugs available to more developing nations.
Polly J. Price is a professor at Emory University School of Law in Atlanta.
Other essays in this series:
James Kassaga Arinaitwe, Global Health Corps & Aspen Institute Fellow / Kampala
Manica Balasegaram, Exec. Director, Access Campaign, Médecins Sans Frontières / Geneva
John Wilbanks, Chief Commons Officer, Sage Bionetworks / Washington, D.C.
Dimitrios Tzalis, Founder & CEO, Taros Chemicals GmbH & Co. KG. / Dortmund
T.V. Mohandas Pai, Chairman, Manipal Global Education Services / Bangalore
Els Torreele, Director, Access to Essential Medicines Initiative, Open Society Foundations / NYC
Tomasz Sablinski, CEO of Transparency Life Sciences / NYC
Zakir Thomas, Open innovation expert & former Project Director of OSDD / Delhi
Matthew Todd, Founder of Open Source Malaria / Sydney & Cambridge